Excluding ancestry‐specific ERG/TMPRSS2 fusion partners, cancer drivers uniquely mutated in Africans included, MFF (eight tumours), FAT4 (7), HTRA3 (7), MC2L2 (6), CHD3 (5), MUC17 (5), and TEC (2), and in Europeans MTCH2 (4) and PAPSS2 (3), representing a longer tail of actionable therapeutic targets for Africans. The gene discussed is ERG; the disease is neoplasm.